AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 2109

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

14 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now
EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Watch now
Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Watch now
NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Watch now
SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Watch now
ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF Watch now
New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD Watch now
ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Watch now
BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Watch now
KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Watch now
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation Watch now

Part 4

Highlights

1 session
3 Trials That Will Change My Practice with Dr Michelle Kittleson Watch now

About the episode

AHA Conference 2024 - Five-Year safety and efficacy follow-up outcomes investigating the non-inferiority of the AMPLATZER Amulet device (Abbott Medical Devices) against the commercially available WATCHMAN (Boston Scientific) device.

 

Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute - HCA Midwest, KS, US) joins us onsite at AHA Conference to discuss the findings from Amulet IDE (NCT02879448).

 

Amulet IDE is a randomized, multi-center, active control, worldwide trial, were patients with non-valvular atrial fibrillation were randomized 1:1 to receive either the Amulet left atrial appendage (LAA) occlusion device or the WATCHMAN LAA closure device. 1,878 patients were randomized for the trial and were followed up at 45 days, 12 months and 18 months. The primary outcome measures were the composite endpoint rate of procedure-related complications or all-cause death or major bleeding, the composite rate of ischemic stroke or systemic embolism, and the rate of device closure.

 

Interview Questions:
1.    What is the importance behind the Amulet IDE trial?
2.    What was the study design and patient population?
3.    What were the key findings?
4.    What are the take-home messages for practice?
5.    What further research is needed in this area?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Arrhythmia Academy.

Faculty Biographies

Dhanunjaya Lakkireddy

Dhanunjaya Lakkireddy

Medical Director and Professor of Medicine

Dr Dhanunjaya Lakkireddy is the Medical Director at Kansas City Heart Rhythm Institute and a Professor of Medicine at the University of Missouri, Columbia. As a trained cardiologist he specialises in the research and education of electrophysiology. He is a Chairman of the ACC Electrophysiology Council as well as a member of the Program Committee in the Heart Rhythm Society.

Dr Lakkireddy has received multiple awards and recognitions, including the Professional Leader of the Year from the Asian Chamber of Commerce, Prevention Magazine Integrative Medicine Award, and Ingram's Heroes in Health Care Award.

He continues to serve as the principal investigator for clinical trials and has published more than 350 articles in the field of electrophysiology. Alongside writing articles, Dr. Lakkireddy is the Editor-in-Chief for the Journal of Atrial Fibrillation, Deputy Editor for the Journal of Interventional Electrophysiology, and editorial board member and reviewer for more than…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.